Treagliptin is a long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor, which is mainly used for the treatment of type 2 diabetes. It has the convenience of being administered once a week. It is necessary to pay attention to key information such as the special drug users and drug interactions.

1. Basic information of the drug

(1) Pharmacological classification: Belonging to the DPP-4 inhibitor class of hypoglycemic drugs, it increases endogenous GLP-1 levels by inhibiting the DPP-4 enzyme.

(2) Dosage form specifications: Commonly used as 100mg tablets, some countries provide 50mg specifications for patients with renal insufficiency.

2 Indications

(1) It is applicable to the blood sugar control of adult type 2 diabetes patients, and can be used as a single drug or combined treatment.

(2) It is not suitable for the treatment of type 1 diabetes or diabetes ketoacidosis.

3 Characteristics of Function

(1) Long acting: with a half-life of about 50 hours, it can be administered once a week.

(2) Glucose dependence: Low risk of hypoglycemia, rare hypoglycemia when used alone.

(3) Weight neutral: Has minimal impact on weight.

4 Research and development and market launch

(1) Developed by Takeda Pharmaceuticals in Japan, it was first approved in Japan in 2015.

(2) It has been launched in multiple Asian countries but has not been approved by Europe and America.